Pharmaust Limited (ASX: PAA), a clinical-stage biotech company, announced a significant achievement in the Phase 2 trial for treating canine B-cell Lymphoma with Monepantel (MPL). Louie, a patient in the trial, has surpassed one year on MPL, defying the poor prognosis associated with this condition-cell Lymphoma in dogs typically leads to fatal outcomes within weeks. Palliative care, such as steroid drugs, may offer temporary relief, but chemotherapy, while extending survival for approximately 12 months, comes with significant adverse events and costs.
Pharmaust's commercial strategy aims to bridge the gap between standard-of-care and chemotherapy by achieving stable disease with minimal side effects, providing an extended median survival of 150 days while maintaining a high Quality of Life (QoL). Louie’s remarkable journey on MPL showcases the potential of this approach, offering hope for both human and canine patients. Pharmaust remains committed to advancing innovative treatments that enhance outcomes and improve QoL for those battling cancer.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 20, 2024
Nov 20, 2024
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
